Neem Biotech

Executive Summary

Neem Biotech is a UK-based private drug discovery company founded in 2015, specializing in antimicrobial research using an anti-virulence approach to combat antibiotic resistance. The company originates from contract research on neem tree medicinal properties and now focuses on discovering novel small molecules. Its business model involves de-risking assets to the preclinical stage before spinning them out into focused subsidiary companies. Despite being private with no disclosed funding or valuation, Neem Biotech's innovative strategy addresses the critical need for new antibiotics. The company's progress is closely tied to its ability to advance preclinical candidates and form partnerships. Key upcoming catalysts include preclinical data readouts, potential spin-out announcements, and collaboration deals. Given the early-stage nature and lack of public financials, the conviction score is moderate, reflecting both the promise of the anti-virulence approach and the inherent uncertainties in drug development.

Upcoming Catalysts (preview)

• Q3 2026Preclinical data release for lead antimicrobial candidate60% success
• H2 2026Announcement of spin-out subsidiary for a specific asset50% success
• Q4 2026New research partnership or licensing deal55% success